Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by fredgoodwinsonon May 29, 2020 1:09pm
119 Views
Post# 31088568

RE:RE:RE:Is MDNA holding TLT back?

RE:RE:RE:Is MDNA holding TLT back?

TLT`s small Trial will be about more than demonstrating superior efficacy - it should be definitive proof of concept for the elegance and superiority of PDT as a treatment modality.

 

Worth looking at Medicenna`s complex and invasive mechanism of drug delivery from their presentation of the 20th of November 2019 (see details below). They can exert beneficial influence and extend life expectancy in respect of those 76% of GBM tumours that over-express IL-4 but this does not eliminate the tumours and such delivery begs the question as to whether such treatment could be repeated?

 

Rutherrin on the other hand can be intravenously administered to find its`way across the blood-brain barrier to selectively accumulate in the tumour. Might it then be activated trans-cranially - i.e. a entirely non-invasive treatment??? That is a big question to which we haven’t yet been told the answer.

 

 

 

 

 

EVENTS AND PRESENTATIONS

24th Annual Meeting of the Society of Neuro-Oncology and 3rd Joint Conference of SNO and Society for CNS Interstitial Delivery of Therapeutics

Wednesday, November 20, 2019

3:10pm MST

Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Recurrent Glioblastoma

Presenter: Dr. Nicholas Butowski, MD – Professor of Neurological Surgery and Director of Translational Research in Neuro-Oncology at The Helen Diller Family Comprehensive Cancer Center, University of California San Francisco

Room: Grand Saguaro East

pastedGraphic.png

Download Presentation

6.1 MB

Bullboard Posts